clinical: search

Clinical study shows biological and clinical activity in relapsed leukemia patients

LUGANO, SWITZERLAND, June 4, 2008 – Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML). The promising interim results from this ongoing clinical trial indicate that single-agent GCS-100 induces apoptosis (programmed cell death) in patients' CLL cells, reduces leukocyte count in some patients and is generally well tolerated. GCS-100 targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis.

The Art and Science of Clinical Decision Making

Thinking about how you make clinical decisions is the first step toward making better ones. Doctors' clinical decision making has received much attention over the last 18 months, due in part to Dr. Jerome Groopman's best-selling book How Doctors Think.1 Before Groopman's book climbed the New York Times best-seller list last year, a November 2006 study in the British Medical Journal reported that the search engine Google was able to arrive at a correct diagnosis 58 percent of the time when presented with three symptoms.2 Reports of the study in the national media raised questions about how we physicians make clinical decisions. Articles in The New Yorker, Time and Newsweek followed,3-5 leaving patients and physicians alike with newfound interest in this critically important skill.

Clinical Data Secures EU Patent for MDR1 - A Key Multi-Drug Resistance Gene

Clinical Data, Inc. (CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that the European Patent Office has granted Patent No. 1232260 to Bernried, Germany-based Epidauros Biotechnologie AG, a wholly-owned subsidiary of Clinical Data, relating to the use of a genetic variant, or biomarker, of the gene MDR1 (also known as ABCB1), which encodes P-glycoprotein (PGP). PGP is an efflux pump expressed in the gut and kidneys but also by tumor cells, and therefore modulates the response to medications by blocking their absorption into the body or into tumors. Classes of drugs transported by PGP include chemotherapeutics, immunosuppressants, and protease inhibitors.

Clinical Data Secures EU Patent for MDR1 - A Key Multi-Drug Resistance Gene

Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that the European Patent Office has granted Patent No. 1232260 to Bernried, Germany-based Epidauros Biotechnologie AG, a wholly-owned subsidiary of Clinical Data, relating to the use of a genetic variant, or biomarker, of the gene MDR1 (also known as ABCB1), which encodes P-glycoprotein (PGP). PGP is an efflux pump expressed in the gut and kidneys but also by tumor cells, and therefore modulates the response to medications by blocking their absorption into the body or into tumors. Classes of drugs transported by PGP include chemotherapeutics, immunosuppressants, and protease inhibitors.

EU patent for Clinical Data's gene MDR1

Clinical Data, Inc., a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that the European Patent Office has granted Patent No. 1232260 to Bernried, Germany-based Epidauros Biotechnologie AG, a wholly-owned subsidiary of Clinical Data, relating to the use of a genetic variant, or biomarker, of the gene MDR1 (also known as ABCB1), which encodes P-glycoprotein (PGP).

LegalView Informs Mesothelioma Blog Readers of A New Clinical Trial Available for Victims of Asbestos-Induced Lung Cancer

blog on an opportunity for pleural mesothelioma cancer victims to participate in a clinical trial being conducted at the Mesothelioma Center at New York-Presbyterian Hospital and Columbia University Medical Center. The clinical trial hopes to improve surgical and radiation treatments for patients of pleural mesothelioma cancer. Currently, the most common treatment for patients of the asbestos-induced cancer is removal of the victim's lung. Individuals who suffer from pleural mesothelioma or any other form of mesothelioma cancer are advised to speak with an experienced

LegalView Informs Mesothelioma Blog Readers of A New Clinical Trial Available for Victims of Asbestos-Induced Lung Cancer

(EMAILWIRE.COM, July 08, 2008 ) Denver, CO - LegalView.com, the number one legal resource on the Web, offered information through its mesothelioma information (http://mesothelioma.legalview.com/blog ) blog on an opportunity for pleural mesothelioma cancer victims to participate in a clinical trial being conducted at the Mesothelioma Center at New York-Presbyterian Hospital and Columbia University Medical Center. The clinical trial hopes to improve surgical and radiation treatments for patients of pleural mesothelioma cancer. Currently, the most common treatment for patients of the asbestos-induced cancer is removal of the victim's lung. Individuals who suffer from pleural mesothelioma or any other form of mesothelioma cancer are advised to speak with an experienced mesothelioma lawyer (http://mesothelioma.

Suven secures European product patent

The European Patent Office (EPO) has granted Suven the product patent, EP 1581492, to its clinical candidate SUVN-502 that is valid until June 2023. EP 1581492 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts. "Potential market opportunity for these indications is more than $18 billion globally. Granting of this patent to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is entering into clinical trials. Securing patent protection for our discoveries enhanced the value of our technologies and products substantially," said Venkat Jasti, CEO, Suven Life Sciences.

Genome Sequencer FLX System plus NimbleGen Sequence Capture Arrays Help Unravel the Cryptic Genetic Changes in Hematological Malignancies

PENZBERG, Germany--(BUSINESS WIRE)--Jul 8, 2008 - The Cancer Genomics Group at Barts and The London Medical School is researching leukemia with the aquisition of the state-of-the-art Genome Sequencer FLX System paired with the Roche NimbleGen Sequence Capture arrays. Researchers, led by Professor Brian Young, will use the combined technology of 454 Sequencing and NimbleGen Sequence Capture Arrays to uncover the genetic changes that are involved in the development of leukemia. The new sequence information will be linked to an existing extensive clinical and cytogenetic database to investigate the relationship between genetic change and the clinical features of this devastating disease. The researchers expect that the new data could have implications for the future therapy and clinical outcome of hematological malignancies.

Clinical Data unit gets EU patent for cancer-related biomarker

Clinical Data Inc., a Newton developer of targeted therapeutics and genetic tests, reports that the European Patent Office has granted the firm’s German subsidiary a patent for a genetic biomarker linked to a gene responsible for blocking the absorption of anti-cancer drugs in tumor cells.

Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System

PRNewswire/ -- Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has resumed European clinical activities on its TOPS(TM) System, a Total Posterior Arthroplasty device designed to treat spinal stenosis with or without facet arthrosis and spondylolisthesis. The procedure was performed by the Lead Clinician of the London Spine Clinic, Mr. John C. Sutcliffe, MB ChB, FRCS.

BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor

BiPar Sciences, Inc. has announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

Unlocking The Promise Of Clinical And Translational Science

If you were sick, wouldn’t you prefer a customized medical treatment that works specifically for you? Or a treatment that prevents you from ever getting sick in the first place? The emerging field of clinical and translational science provides the bridging force that transforms lab discoveries into customized, patient-specific therapy.

Draeger Medical Launches Online Draeger Medical Service Community for Clinical and Biomedical Customers

TMCNet: Draeger Medical Launches Online Draeger Medical Service Community for Clinical and Biomedical Customers

LegalView Blog Announces Recruitment of Mesothelioma Victims for New Clinical Trial Combining Chemotherapy and Radiation Treatments

LegalView, the most comprehensive legal resource available on the Web, released details of a newly advertised clinical trial that will target radiation and chemotherapy treatments rather than surgery for mesothelioma patients. The study is for individuals suffering from malignant pleural mesothelioma, which is often considered the most deadly form of mesothelioma cancer. The trial will take approximately 13 weeks and will involve exploratory surgery as well as chemotherapy and radiotherapy, which will be administered directly into the affected area.

LegalView Blog Announces Recruitment of Mesothelioma Victims for New Clinical Trial Combining Chemot

Denver, CO (PRWEB) July 12, 2008 -- LegalView, the most comprehensive legal resource available on the Web, released details of a newly advertised clinical trial that will target radiation and chemotherapy treatments rather than surgery for mesothelioma patients. The study is for individuals suffering from malignant pleural mesothelioma, which is often considered the most deadly form of mesothelioma cancer. The trial will take approximately 13 weeks and will involve exploratory surgery as well as chemotherapy and radiotherapy, which will be administered directly into the affected area.

LegalView Blog Announces Recruitment of Mesothelioma Victims for New Clinical Trial Combining Chemotherapy and Radiation Treatments

(EMAILWIRE.COM, July 12, 2008 ) Denver, CO - LegalView, the most comprehensive legal resource available on the Web, released details of a newly advertised clinical trial that will target radiation and chemotherapy treatments rather than surgery for mesothelioma patients. The study is for individuals suffering from malignant pleural mesothelioma, which is often considered the most deadly form of mesothelioma cancer. The trial will take approximately 13 weeks and will involve exploratory surgery as well as chemotherapy and radiotherapy, which will be administered directly into the affected area. Mesothelioma cancer is caused by the inhalation of asbestos fibers and dust, which can occur anywhere asbestos has been previously used, although it is most commonly found in insulation within the construction industry.

Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV

Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV

Quantitative In Vivo Islet Potency Assay in Normoglycemic Nude Mice Correlates With Primary Graft Function After Clinical Transplantation.

Quantitative In Vivo Islet Potency Assay in Normoglycemic Nude Mice Correlates With Primary Graft Function After Clinical Transplantation.

Cold Jet Helping RobotWorx to Refurbish Industrial Robots

Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation

NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting

NEW YORK (May 29, 2008) -- Leading oncologists and cancer researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center are presenting new basic and clinical research findings at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, May 30 to June 3.

Nanotech Revives a Cancer Drug

In the 1990s, a cancer drug called TNP-470 dramatically increased life span for some patients and led to complete cancer regression in others. But when neurotoxicity was detected in some patients, clinical trials were halted. This is a common problem: many drugs that show great promise in the lab fail in clinical trials due to unforeseen toxicity. Nanomedicine, however, promises a way to make safer, more effective versions of such drugs. Researchers at Children's Hospital Boston have created and tested in mice a safer version of TNP-470.

Clinical Data Secures EU Patent for MDR1 - A Key Multi-Drug Resistance Gene

StreetInsider.com

Clinical Data, 454 Life Sciences team up to study crop genes

Subscribe to Mass High Tech: The Journal of New England Technology Subscribe to Mass High Tech: The Journal of New England Technology

Clinical Data, 454 Life Sciences team up to study crop genes

Subscribe to Mass High Tech: The Journal of New England Technology Subscribe to Mass High Tech: The Journal of New England Technology

Search took 0.02 seconds.